Does the ypTNM-stage adequately predict long-term survival rates in gastric cancer patients receiving neoadjuvant chemotherapy followed by radical resection?

References

• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.N Engl J Med. 2006;355(1):11–20. doi:10.1056/NEJMoa055531.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–1957. doi:10.1016/S0140-6736(18)32557-1.
   PubMed Web of Science ®Google Scholar
• Lin JX, Yoon C, Desiderio J, et al. Development and validation of a staging system for gastric adenocarcinoma after neoadjuvant chemotherapy and gastrectomy with D2 lymphadenectomy. Br J Surg. 2019;106(9):1187–1196. doi:10.1002/bjs.11181.
   PubMed Web of Science ®Google Scholar
• Mranda GM, Xue Y, Zhou XG, et al. Revisiting the 8th AJCC system for gastric cancer: a review on validations, nomograms, lymph nodes impact, and proposed modifications. Ann Med Surg (Lond). 2022;75:103411.
   PubMed Web of Science ®Google Scholar
• Blumenthaler AN, Newhook TE, Ikoma N, et al. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol. 2021;123(4):911–922. doi:10.1002/jso.25081.
   PubMed Web of Science ®Google Scholar
• Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14(9):611–622. doi:10.1038/nrc3793.
   PubMed Web of Science ®Google Scholar
• Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer. 2010;10(12):871–877. doi:10.1038/nrc2933.
   PubMed Web of Science ®Google Scholar
• Weston WA, Barr AR. A cell cycle centric view of tumour dormancy. Br J Cancer. 2023. doi:10.1038/s41416-023-02401-z.
   PubMed Web of Science ®Google Scholar
• Li Z, Wang Y, Shan F, et al. ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system. Gastric Cancer. 2018;21(6):977–987. doi:10.1007/s10120-018-0830-1.
   PubMed Web of Science ®Google Scholar
• Li Z, Wang Y, Ying X, et al. Different prognostic implication of ypTNM stage and pTNM stage for gastric cancer: a propensity score-matched analysis. BMC Cancer. 2019;19(1):80. doi:10.1186/s12885-019-5283-3.
   PubMed Web of Science ®Google Scholar
• Thomaschewski M, Hummel R, Petrova E, et al. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours. World J Gastroenterol. 2018;24(13):1429–1439. doi:10.3748/wjg.v24.i13.1429.
   PubMed Web of Science ®Google Scholar
• Rice TW, Ishwaran H, Kelsen DP, et al. Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016;29(8):906–912. doi:10.1111/dote.12538.
   PubMed Web of Science ®Google Scholar
• Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64(1):31–49. doi:10.1111/apm.1965.64.1.31.
   PubMedGoogle Scholar
• Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–449. doi:10.1016/S1470-2045(10)70070-X.
   PubMed Web of Science ®Google Scholar
• Shimizu K, Ito K, Matsunaga N, et al. Diagnosis of gastric cancer with MDCT using the water-filling method and multiplanar reconstruction: CT-histologic correlation. AJR Am J Roentgenol. 2005;185(5):1152–1158. doi:10.2214/AJR.04.0651.
   PubMed Web of Science ®Google Scholar
• Sandø AD, Fougner R, Grønbech JE, et al. The value of restaging CT following neoadjuvant chemotherapy for resectable gastric cancer. A population-based study. World J Surg Oncol. 2021;19(1):212. doi:10.1186/s12957-021-02313-3.
   PubMed Web of Science ®Google Scholar
• Sandø AD, Fougner R, Røyset ES, et al. Response evaluation after neoadjuvant chemotherapy for resectable gastric cancer. Cancers (Basel). 2023;15(8):2318. doi:10.3390/cancers15082318.
   PubMed Web of Science ®Google Scholar
• Prasad P, Sivaharan A, Navidi M, et al. Significance of neoadjuvant downstaging in gastric adenocarcinoma. Surgery. 2022;172(2):593–601. doi:10.1016/j.surg.2022.03.005.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147(8):W163–94. doi:10.7326/0003-4819-147-8-200710160-00010-w1.
   PubMed Web of Science ®Google Scholar
• Sada YH, Smaglo BG, Tan JC, et al. Prognostic value of nodal response after preoperative treatment of gastric adenocarcinoma. J Natl Compr Canc Netw. 2019;17(2):161–168. doi:10.6004/jnccn.2018.7093.
   PubMed Web of Science ®Google Scholar
• Wu L, Xing Z, Huang M, et al. Nodal downstaging to ypN0 after neoadjuvant chemotherapy positively impacts on survival of cT4N + GC/GEJ patients. J Surg Oncol. 2022;126(8):1403–1412. doi:10.1002/jso.27065.
   PubMed Web of Science ®Google Scholar
• Zhong Q, Chen QY, Parisi A, et al. Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: a multi-institutional study. Oncologist. 2021;26(1):e99–e110. doi:10.1634/theoncologist.2020-0022.
   PubMed Web of Science ®Google Scholar
• Li Z, Xiao Q, Wang Y, et al. A modified ypTNM staging system-development and external validation of a nomogram predicting the overall survival of gastric cancer patients received neoadjuvant chemotherapy. Cancer Manag Res. 2020;12:2047–2055. doi:10.2147/CMAR.S236696.
   PubMed Web of Science ®Google Scholar
• Allgayer H, Leupold JH, Patil N. Defining the "metastasome": perspectives from the genome and molecular landscape in colorectal cancer for metastasis evolution and clinical consequences. Semin Cancer Biol. 2020;60:1–13. doi:10.1016/j.semcancer.2019.07.018.
   PubMed Web of Science ®Google Scholar
• Reiter JG, Makohon-Moore AP, Gerold JM, et al. Reconstructing metastatic seeding patterns of human cancers. Nat Commun. 2017;8(1):14114. doi:10.1038/ncomms14114.
   PubMed Web of Science ®Google Scholar
• Wu P, Gao W, Su M, et al. Adaptive mechanisms of tumor therapy resistance driven by tumor microenvironment. Front Cell Dev Biol. 2021;9:641469. doi:10.3389/fcell.2021.641469.
   PubMed Web of Science ®Google Scholar
• Knight WRC, Baker CR, Griffin N, et al. Does a high mandard score really define a poor response to chemotherapy in oesophageal adenocarcinoma? Br J Cancer. 2021;124(10):1653–1660. doi:10.1038/s41416-021-01290-4.
   PubMed Web of Science ®Google Scholar
• Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009;9(4):302–312. doi:10.1038/nrc2627.
   PubMed Web of Science ®Google Scholar
• Stoecklein NH, Klein CA. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer. 2010;126(3):589–598. doi:10.1002/ijc.24916.
   PubMed Web of Science ®Google Scholar
• Kamarajah SK, Navidi M, Wahed S, et al. Significance of neoadjuvant downstaging in carcinoma of esophagus and gastroesophageal junction. Ann Surg Oncol. 2020;27(9):3182–3192. doi:10.1245/s10434-020-08358-0.
   PubMed Web of Science ®Google Scholar
• Rice TW, Lerut TE, Orringer MB, et al. Worldwide esophageal cancer collaboration: neoadjuvant pathologic staging data. Dis Esophagus. 2016;29(7):715–723. doi:10.1111/dote.12513.
   PubMed Web of Science ®Google Scholar
• Zanoni A, Verlato G, Giacopuzzi S, et al. ypN0: does it matter how you get there? Nodal downstaging in esophageal cancer. Ann Surg Oncol. 2016;23(Suppl 5):998–1004. doi:10.1245/s10434-016-5440-8.
   PubMed Web of Science ®Google Scholar
• Ikoma N, Estrella JS, Hofstetter W, et al. Nodal downstaging in gastric cancer patients: promising survival if ypN0 is achieved. Ann Surg Oncol. 2018;25(7):2012–2017. doi:10.1245/s10434-018-6471-0.
   PubMed Web of Science ®Google Scholar
• Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–1721. doi:10.1200/JCO.2010.33.0597.
   PubMed Web of Science ®Google Scholar
• Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol. 2007;25(15):2107–2116. doi:10.1200/JCO.2006.09.5224.
   PubMed Web of Science ®Google Scholar
• Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009;12(1):6–22. doi:10.1007/s10120-008-0492-5.
   PubMed Web of Science ®Google Scholar
• Yan C, Zhu ZG, Yan M, et al. Value of multidetector-row computed tomography in the preoperative T and N staging of gastric carcinoma: a large-scale Chinese study. J Surg Oncol. 2009;100(3):205–214. doi:10.1002/jso.21316.
   PubMed Web of Science ®Google Scholar